Quarterly report [Sections 13 or 15(d)]

Subsequent Events

v3.26.3
Subsequent Events
9 Months Ended
Sep. 30, 2026
Subsequent Events [Abstract]  
Subsequent Events

Note 12 – Subsequent Events

 

Generian Agreement

 

On October 12, 2026, Vidya Therapeutics Operating LLC (“Vidya Subsidiary”), a wholly owned subsidiary of the Company, entered into a Collaboration and Exclusive Option Agreement (the “Generian Agreement”) with Generian Pharmaceuticals, Inc. (“Generian”) to advance a program of orally administered inhibitors of the neonatal Fc receptor (FcRn) through nomination of a development candidate.

 

Under the Generian Agreement, Generian granted Vidya Subsidiary an exclusive option to obtain an exclusive, worldwide license to the related technology. Vidya Subsidiary paid a non-refundable upfront payment of $4.0 million and research and development reimbursement of $0.5 million. The Company may fund additional research and development activities intended to advance the program through development candidate nomination, if approved by the Company.

 

Vidya Subsidiary is not obligated to exercise the option. If exercised, Vidya Subsidiary would pay a non-refundable exercise fee, be obligated to pay clinical, regulatory and sales-based milestone payments and pay a royalty fee on future sales of the licensed asset. The option structure is intended to provide Vidya Subsidiary with the opportunity to evaluate the program’s continued development based on the results of the research and development activities conducted during the option period. We guaranteed Vidya Subsidiary’s payment obligations under the Generian Agreement.

 

A member of our Board also serves as a member of Generian’s Board of Directors. The Generian Agreement was reviewed and approved by our Board, with that Director recusing themselves from the deliberations and vote.

 

Our accounting evaluation of the Generian Agreement is ongoing, and its preliminary conclusion, which is subject to change, is that the transaction represents an asset acquisition of in-process research and development with no alternative future use. On that basis, we currently expect to record the non-refundable upfront payment as research and development expense in the fourth quarter of 2026, with the funded research costs expensed as the services are performed.

 

Appointment of Chief Operating Officer

 

On November 2, 2026, our Board approved the appointment of Gregory J. Flesher as Chief Operating Officer, effective November 4, 2026. In connection with his appointment, the Company entered into an employment agreement with Mr. Flesher which is incorporated by reference in Exhibit 10.4.